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Abstract
Background: Squamous cell carcinoma antigen-immuno-
globulin M (SCCA-IgM) is a useful biomarker for the risk
of development of hepatocellular carcinoma (HCC) in
patients with cirrhosis due to its progressive increase asso-
ciated to HCC evolution. In patients with cirrhosis, other
assays have been affected by interfering reactivities of IgM.
In this study, the analytical specificity of the SCCA-IgM
assay was assessed by evaluating SCCA-IgM measurement
dependence on different capture phases, and by measuring
the recovery of SCCA-IgM reactivity following serum
fractionation.
Methods: Serum samples from 82 patients with cirrhosis
were analyzed. SCCA-IgM was measured using the reference
test (Hepa-IC, Xeptagen, Italy) that is based on rabbit oli-
goclonal anti-squamous cell carcinoma antigen (SCCA) and
a dedicated ELISA with a mouse monoclonal anti-SCCA as
the capture antibody.
Results: SCCA-IgM concentrations measured with the ref-
erence assay (median values87 AU/mL) were higher than
those measured with the mouse monoclonal test (median
values78 AU/mL). However, the differences in the SCCA-
IgM distribution were not statistically significant (p)0.05).
When SCCA-IgM concentrations measured with both tests
were compared, a linear correlation was found (rs0.77,
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p-0.05). Fractionation of the most reactive sera by gel-fil-
tration chromatography showed that total recovery of SCCA-
IgM reactivity was seen only in the fractions corresponding
to components with a molecular weight higher than IgM and
SCCA ()2000 kDa) with both tests.
Conclusions: The equivalence of both SCCA-IgM assays
and the absence of reactivity not related to immune com-
plexes support the analytical specificity of SCCA-IgM meas-
urements. The results validate the assessment of SCCA-IgM
for prognostic purposes in patients with cirrhosis.
Clin Chem Lab Med 2010;48:217–23.
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Introduction
Tumour growth may trigger an immunogenic response that
may eliminate malignant cells before they become clinically
evident. When malignant cells develop a mechanism to
escape the selective pressure of the immune system, the neo-
plasm becomes free to continue growing. Other than the
elimination and escape phase, the cancer immunoediting
model which is an updated and refined cancer immunesur-
veillance theory, predicts a temporary equilibrium state
between the immune system and the tumour. In this phase,
tumour growth is under the control of the immune system
and continues to exert selective suppression on the trans-
formed cells (1–5). At present, a large number of animal
studies (3) and clinical observations in humans (4, 5) provide
evidence supporting the cancer immunoediting theory. In
patients with different types of cancer including liver, colo-
rectal and prostate cancer, it is possible to detect immuno-
globulin M (IgM) antibodies bound to cancer biomarkers
(6–10).
It might be possible that these biomarker-IgM immune
complexes are involved in cancer immunoediting, reflecting
host immune protective mechanisms trying to apply selective
pressure on neoplastic cells in order to combat the tumour.
In hepatocellular carcinoma (HCC) several biomarkers can
be detected that are associated with IgM. The assessment of
biomarker-IgM immune complexes has a higher diagnostic
value compared with measurement of the free biomarker.
This has been reported for a-fetoprotein (AFP) and des-g-
carboxy-prothrombin (DCP), which are conventional sero-
logical biomarkers of HCC, and also for the newly described
HCC biomarker squamous cell carcinoma antigen (SCCA)
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(7, 8). In addition, the clinical value of SCCA-IgM as a
predictive biomarker of evolution of HCC in patients with
cirrhosis has been also reported, demonstrating that the
increase in serum concentrations over time of SCCA-IgM in
patients with cirrhosis was associated to higher risk of devel-
opment of HCC (11). The behaviour of serum concentrations
of SCCA-IgM was studied in two groups of cirrhotic patients
with similar clinical profiles at presentation and followed
prospectively. A significant increase in serum SCCA-IgM
was found only in the group of patients who developed HCC
during a median follow-up of 4 years. During the same time
interval, the group of patients with cirrhosis who did not
progress to liver cancer had unchanged concentrations of
SCCA-IgM (3). The measurement of serum SCCA-IgM
could represent a helpful tool for screening patients at risk
of HCC, for which conventional serological biomarkers have
been shown to be ineffective (12).
Heterophilic antibodies, naturally occurring human anti-
bodies to immunoglobulins of animal origin, or autoanti-
bodies, could be a source of analytical interference in
immunometric assays (13). Circulating endogenous IgM
could bind the capture antibodies of the test and cause mis-
leading results. Also, interference in other immunoassays by
interfering IgM has also been reported (14–16). However,
endogenous IgM interference is often undetermined in many
immunoassays despite numerous reports highlighting its seri-
ous consequences (13). Interference from IgM depends on
the nature of the antibody used in the capture phase. As a
consequence different antibodies respond differently to this
interference (13–16).
In this study, we assessed SCCA-IgM concentrations in
patients with cirrhosis by a rabbit oligoclonal and a mouse
monoclonal antibody (mAb) as capture antibodies in two dif-
ferent ELISA tests in order to evaluate whether the SCCA-
IgM assay is affected by interference from IgM. The role of
IgM in measurement of SCCA-IgM was further assessed by
evaluating the ability of both antibodies to recognise SCCA-
IgM in serum samples following removal of free IgM by gel
filtration chromatography.
Materials and methods
Patients
Serum from 82 patients with cirrhosis wM/F ratio 3/1; mean age"
standard deviation (SD): 56"9 yearsx was collected from the Liver
Unit of the Department of Clinical and Experimental Medicine, Uni-
versity of Padua, according to institutional approved procedures.
The etiology of liver cirrhosis was alcohol abuse in 38 patients,
HCV infection in 25 patients, HBV infection in six patients, coin-
fection with HCV/HBV in six patients, and alcohol and viral infec-
tion (HBV and/or HCV) in seven patients. All patients gave fully
informed consent authorising use of blood for research purpose
prior to collection of samples. Patients underwent regular liver
ultrasound screening to exclude the occurrence of hepatic nodules.
SCCA-IgM assays
Serum concentrations of SCCA-IgM were measured with the ref-
erence test based on a rabbit oligoclonal anti-SCCA antibody (Hepa-
IC, Xeptagen, Italy) and with an ELISA assay that used a mouse
mAb anti-human SCCA in the capture phase to reduce interference
from IgM autoantibodies. Briefly, 96-well ELISA plates were coated
with 1 mg of mAb anti-SCCA in 100 mL of phosphate buffered
saline (PBS) per well at 48C over night, and then blocked for 2 h
with 1% bovine serum albumin (BSA) in PBS. After blocking,
100 mL of serially diluted reference standards and samples in PBS
containing 1% BSA and 0.05% Tween20 (P-B-T) were incubated
for 1 h at room temperature. The SCCA-IgM complex was revealed
with use of peroxidase-conjugated anti-human IgM and developed
with ABTS and hydrogen peroxidase as chromogenic substrates.
The amount of SCCA-IgM complex was expressed in arbitrary units
per mL (AU/mL).
Gel filtration
One hundred microlitres of serum was analysed using a BioSep SEC
S-4000 gel-filtration column (Phenomenex, Macclesfield, Cheshire,
UK). The elution was performed in PBS at a flow rate of 1 mL/min,
and sample absorbance was monitored at 280 nm. Serum fractions
were collected every 15 s and immune reactivity was tested by
ELISA as described above, but using 3,39,5959-tetramethylbenzidine
(TMB) as chromogenic substrate. Before the samples were loaded,
a calibration run was performed according to the manufacturer’s
instructions.
Localisation of predicted epitopes on the SCCA
surface
The antigenic epitopes of human SCCA 1 (Serpin B3) were pre-
dicted from the primary sequence of the protein (Swiss-Prot acces-
sion number P29508) using the bioinformatics server of the Cancer
Vaccine Centre group of Dana-Farber Cancer Institute available at
the URL http://immunax.dfci.harvard.edu/Tools/antigenic.pl. The
application exploits the method of Kolaskar and Tongaonkar (17),
which is based on the observation that hydrophobic amino acid
residues, such as Cys, Leu and Val occurring on the surface of a
protein are likely to be part of an antigenic site. Predictions are
based using a table that reflects the frequency of the occurrence of
individual amino acid residues in experimentally known segmental
epitopes. The algorithm scans the protein sequence, calculates the
residue propensity belonging to an antigenic site for a sliding win-
dow of seven residues, and calculates an average score for the whole
protein. All peptides with a minimum size of eight residues that
show a score above the protein average are marked as potentially
antigenic. The reported accuracy of the method is ;75% (17).
The three-dimensional (3D) structure of SCCA, determined by
X-ray analysis (18), was obtained from Protein Data Bank (19)
(PDB ID: 2ZV6). The structure of SCCA was displayed using
molecular modelling software (Insight-II 2000, Accelrys, San
Diego, CA, USA) and the surface area of selected residues was
computed with the Connolly algorithm (20).
Statistical analyses
All analyses were performed using Analyse-it software (Analyse-
it software, Leeds, UK). Statically significant differences between
the two ELISA tests for SCCA-IgM were determined with the
Mann-Whitney U-test. A 2-tailed p-value of -0.05 was used to
determine statistical significance. The Pearson product-moment cor-
relation coefficient (PMCC) was used to calculate the linear corre-
lation between the ELISA tests and a Bland-Altman plot was used
to evaluate agreement.
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Table 1 Intra- and inter-assay coefficients of variation (CV) for
nine serum samples.
Sample SCCA-IgM, Intra-assay Inter-assay
ID AU/mL CV, % CV, %
1 817 12.8 8.7
2 847 2.1 2.8
3 1523 12.9 5.1
4 265 3.4 1.2
5 276 1.7 2.9
6 331 1.8 6
7 121 2.5 7.7
8 143 3.9 1.9
9 198 6.6 4.2
The intra-assay CV was determined by repeated sample analysis
(ns8) with one assay; the inter-assay CV was estimated from five
independent assays with samples tested in triplicate.
Results
A total of 82 serum samples from patients with cirrhosis
were analysed for the presence of SCCA-IgM using the ref-
erence assay that employed an oligoclonal anti-human SCCA
capture antibody (on the solid phase) and a test based on a
mouse monoclonal anti-human SCCA antibody.
The ability of the assay that utilised monoclonal anti-
human SCCA to detect SCCA-IgM immune complexes was
evaluated by testing the seven calibrators of the SCCA-IgM
reference assay. The calibration range of both assays was
12.5–200 AU/mL measured on a semi-logarithmic scale, and
from 3.1 to 12.5 AU/mL evaluated with a linear scale.
The intra- and inter-assay variation was 5.02% and 5.14%,
respectively, for the test using mouse mAb anti-human
SCCA as capture antibody evaluated with standard calibra-
tors. Variability of the SCCA-IgM reference assay was
3.21% for intra-assay variation and of 1.62% for inter-assay
variation.
In both assays the serum concentrations of SCCA-IgM
expressed in AU/mL were determined by interpolation of the
absorbance of eight-fold diluted samples on the calibration
curves plotted with SCCA-IgM calibrators.
The reproducibility of SCCA-IgM reference assay was
measured using nine serum samples from cirrhotic patients,
three samples with values of SCCA-IgM of 817, 847 and
1523 AU/mL, which fell within the upper limits of the cal-
ibration curve, three samples with values of 265, 276 and
331 AU/mL, which fell in the middle range of the calibration
curve, and three samples with values of 121, 143 and
198 AU/mL corresponding to the bottom of the semi-loga-
rithmic calibration range. The calculated mean values of
intra-assay variation among the three samples were 9.26%,
2.30% and 4.30% for serum samples falling into the top,
middle and bottom range of the calibration, respectively. The
mean values of inter-assay reproducibility for samples in the
upper, middle and lower range of the calibration were 5.53%,
3.37% and 4.60%, respectively (Table 1).
SCCA-IgM concentrations measured with the reference
assay (median values87 AU/mL, concentration range:
48–1587 AU/mL) were higher than those measured with the
assay using mouse mAb (median values78 AU/mL, con-
centration range: 62–470 AU/mL) (Figure 1, Table 2). How-
ever, comparison of the two assays showed linear correlation
for SCCA-IgM (rs0.77, p-0.001, Figure 2A). The distri-
bution of serum concentrations of SCCA-IgM measured with
the reference test was not different from those measured with
the assay using mouse mAb (Mann-Whitney U-test two-tail
ps0.3675). A Bland-Altman plot was produced to show
the degree of agreement between serum concentrations of
SCCA-IgM measured using both methods (Figure 2B).
Despite the fairly good correlation, the trend observed in the
Bland-Altman plot indicates a poor relationship when serum
values of SCCA-IgM are )437.1 AU/mL; the upper limit
of agreement calculated as the mean difference (69.8
AU/mL) plus 1.96 SDs (SDs187.4 AU/mL).
To demonstrate that the SCCA-IgM assay was not affected
by interference from IgM, we measured the recovery of
SCCA-IgM reactivity following serum fractionation of the
ten most reactive samples in both assays. Fractions were col-
lected from the column every 15 s and tested for the presence
of SCCA-IgM. Strong reactivity, corresponding to total
recovery of SCCA-IgM, was obtained for both assays in the
fractions eluting with high molecular weights at 6.30–7.15
min (Figure 3). The calibration of the gel-filtration system
led to the estimation of the SCCA-IgM molecular weight
above 2000 kDa.
To better understand the poor relationship between the ref-
erence assay and the mouse monoclonal assay for serum
values of SCCA-IgM at concentrations )437.1 AU/mL, we
performed an analysis of SCCA using available structural
information (18) to estimate the number of putative antigenic
sites localised on the SCCA surface. The antigenic site pre-
diction tool available at the bioinformatics server of the
group of Cancer Vaccine Centre of Dana-Farber Cancer
Institute returned 13 putative antigenic peptide sequences
(Table 3) for the 390 residues of SCCA with an average
antigenic propensity of 1.01. Among the 13 sequences, four
are completely located on the surface of SCCA. Localisation
of the peptide sequences on the protein surface and the area
of the surface patch formed by these sequences are shown
in Figure 4. To identify probable antibody binding sites
among these patches, we analysed over 20 selected crystal
structures of protein-Fab complexes deposited in the PDB
(19). We analysed these structures in terms of average area
and topology of the binding motifs recognised by Fab. The
analysis showed that, in general, the Fab binding motifs on
the proteins form a continuous surface patch of a roughly
oval shape with flat topology and an average surface area of
550"135 A˚ 2, which is typically composed of residues orig-
inating from discontinuous sequences. The predicted anti-
genic determinants on SCCA with the largest surface area
comprise the three sequences Gln51 – Asp60, Gly79 –
Thr90, Gly109 – Phe136 (Table 3).
Discussion
The major function of the immune system is protection from
dangerous effects of the environment. Normal individuals
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Figure 1 Distribution of SCCA-IgM serum concentrations in 82 patients with cirrhosis measured with the SCCA-IgM reference assay and
with the mouse monoclonal method.
*SCCA-IgM measured with reference assays1587 AU/mL.
Table 2 Comparison of distribution of SCCA-IgM concentra-
tions measured with the reference test and with the mouse mono-
clonal test.
Parameters Reference assay, Mouse monoclonal
AU/mL test, AU/mL
Means value"SD 173"235 104"69
Median value 87 78
Concentration range 48–1587 62–470
Figure 2 Comparison of serum concentrations of SCCA-IgM
measured with the reference assay and with the monoclonal test.
(A) Linear correlation of the distribution of SCCA-IgM concentra-
tions measured with reference assay and monoclonal test rs0.77,
p-0.0001. (B) Bland-Altman difference plot for SCCA-IgM meas-
ured with both tests. The mean difference and the limits of agree-
ment are indicated.
express various amounts of immunoglobulins in body fluids.
These antibodies play an important role in induction of
immune responses, representing a network of antibodies and
autoantibodies that react with external non-self antigen and
with self antigens, respectively (21, 22). Innate or natural
immunity acts as the first line of defense, and also acts as
the link between acquired immunity and immunological
memory (21, 23). Polyreactive natural autoantibodies are pri-
marily IgM that can bind with low affinity, but with high
avidity, different markers of cancer growth including those
with particular modifications, different glycosylation pat-
terns, or characteristic variations in circulating concentra-
tions in cancer-associated markers (23). Multivalent IgMs are
usually considered the main component of innate immunity,
with the binding capacity for a wide range of tumour markers
(24, 25).
The occurrence of IgM immune complexes with diagnos-
tic value has been found in different human tumours (6–10),
and also in other pathologic conditions (26, 27).
In the case of HCC, the diagnostic value of serum con-
centrations of SCCA-IgM has been demonstrated (7). Its pos-
sible role as a biomarker for risk of HCC development has
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Figure 3 Serum fractionation by gel filtration chromatography.
(A) Gel-filtration profile of a serum sample. (B) ELISA character-
isation of collected fractions.
Figure 4 Ribbon representation of the backbone (left) and molec-
ular surface (right) of SCCA, front (top) and back side (bottom)
views.
For the colour coding of the sequences see Table 3.
Table 3 Predicted antigenic peptide sequences in the SCCA and their locations on the molecular surface.
No. Start–end Sequence Peak Surface Colourc Note
propensitya areab, A˚
1 12–18 MFDLFQQ 1.06 219 Red On surface
2 27–44 IFYSPISITSALGMVLLG 1.13 239 Yellow Buried
3 51–60 QQIKKVLHFDd 1.15 429 Light blue On surface
4 79–90 GNVHHQFQKLLTe 1.09 551 Light purple On surface
5 109–136 GEKTYLFLQEYLDAIKKFY 1.12 1301 White On surface
QTSVESVDF
6 171–182 NTTLVLVNAIYF 1.18 192 Blue Buried
7 216–234 YTSFHFASLEDVQAKVLEI 1.13 730 Brown Two surface patches,
partially buried
8 241–248 LSMIVLLP 1.16 48 Orange Buried
9 278–287 TRVDLHLPRF 1.12 234 Dark blue Three surface patches,
partially buried
10 320–336 SRGLVLSGVLHKAFVEV 1.20 453 Cyan Several surface patches,
partially buried
11 342–352 EAAAATAVVGF 1.14 n.a.f – Probably on surface
12 363–372 FHCNHPFLFF 1.13 224 Grey Several surface patches,
partially buried
13 379–386 NSILFYGR 1.03 202 Pink Several small surface
patches, partially buried
aMaximum propensity score of a residue within the indicated antigenic peptide sequence. bTotal molecular surface of SCCA molecule is
equal to 14,472 A˚ 2. cColouring scheme, Figure 4, base colour of SCCA – light green. dResidues 60–81 are missing in the crystal structure
due to poor electron density (18). eResidues of the four largest surface patches that actually contribute to the surface area are shown in bold
face. fNot available.
been proposed in a prospective study of two groups of cir-
rhotic patients with or without HCC evolution. In this study,
an increase in circulating SCCA-IgM was associated with
the development of HCC (11). While conventional serum
biomarkers failed in the screening of cirrhotic patients in
HCC surveillance programmes, SCCA-IgM has shown
promise (12). To evaluate the analytical specificity of the
SCCA-IgM assay, we compared the reference ELISA assay,
based upon rabbit oligoclonal antibody to human SCCA,
with a dedicated immunometric test using a mAb anti-human
SCCA as capture antibody.
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In our study, the distribution of SCCA-IgM in serum from
82 patients with cirrhosis was not significantly different
using both tests. However, some lack of agreement between
the assays at higher SCCA-IgM concentrations was demon-
strated by Bland-Altman analysis. This likely reflected the
lower binding capacity of the mAb compared to the oligo-
clonal antibody. The recovery of SCCA-IgM reactivity fol-
lowing gel-filtration was tested using both assays. In both
cases, the recovery of total SCCA-IgM reactivity was seen
in the fractions corresponding to high molecular weight pro-
teins only ()2000 kDa). Since SCCA-IgM concentrations
measured with the reference assay were always higher than
those measured with the mouse monoclonal test, the antibody
binding capacity for SCCA was investigated using an in-
silico analysis of putative antigenic sites.
Although experimental evidences suggest the presence of
at least two distinct antigenic determinants on the SCCA
surface (28), a detailed characterisation of SCCA antigenic
sites is not available. The presence of two or more distinct
antigenic sites on the SCCA surface with adequate size and
topology for antibody recognition as predicted by in silico
analysis may provide significantly different modes of bind-
ing of the SCCA-IgM immune complexes to monoclonal
anti-SCCA antibodies compared to oligoclonal anti-SCCA.
In fact, oligoclonal antibodies may capture SCCA-IgM
immune complexes that do not bind monoclonal monospe-
cific anti-SCCA antibody. The test with the mAb might
underestimate total circulating immune complexes due to
steric hindrance from the enormous mass of IgM (900 kDa)
covering the SCCA surface (45 kDa) which is the binding
site recognised by the mAb. Alternatively, lack of agreement
between the assays at higher SCCA-IgM concentrations
could be due to binding capacity of SCCA-IgM in the mouse
monoclonal test. Despite these considerations, the overall
results showed good correlation for measuring SCCA-IgM
concentrations.
SCCA-IgM immunoreactivity in both assays was related
to the presence of the immune complexes only, and was not
affected by other serum components. This supports the ana-
lytical specificity of the SCCA-IgM assay and validates its
usefulness in HCC surveillance programme.
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